Study S001911

A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injections of GSK 716155 in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT00354536
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: COMPLETED
Enrollment: 60
Start: 2006-02
Primary completion: 2006-09
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:GSK716155 subcutaneous injections; BIOLOGICAL:placebo injection
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

blood plasma levels of GSK716155 [on days 2 & 9]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018591	Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Young MA, Postgraduate medicine	2014	Other trial	PMID 25387217 DOI	cites ClinicalTrials.gov:NCT00354536; registry reference DERIVED:25387217